Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
about
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersEmerging drugs for the treatment of anxietyThe safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.Pharmacological treatment for generalized anxiety disorder in adults: an update.New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis.INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALSEfficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorderVortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.Vortioxetine: a review of its use in major depressive disorder.Vortioxetine for the treatment of major depressive disorder.The efficacy of vortioxetine for the treatment of major depressive disorder.The impact of medication on health-related quality of life in patients with generalized anxiety disorder.Structures and physicochemical properties of vortioxetine salts.A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients.Crystal structures of vortioxetine and its methanol monosolvate.Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.Vortioxetine: first global approval.Efficacy of vortioxetine in working patients with generalized anxiety disorder.An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.
P2860
Q26796436-3FA05AB6-FC03-4012-B5E4-4C0D585D9904Q27009995-4269108A-7075-4031-AA9D-C82A80A21F8BQ28083141-9EEAF35C-4BC6-48E3-B816-49AEFD6FB0B8Q31044175-27614DE7-F6BD-481A-99EB-406723CEEBF8Q34484276-5B59E5F9-A34F-4FEA-8BAA-1CEC52FBF812Q34676776-29500768-A507-4C1C-A0F7-79D7629D5387Q36008269-CD484BA2-8D79-4C37-9FA6-46AD640975DEQ37041164-A9F2199F-525D-498E-9EEA-8EDF365FDCABQ37692558-8DC36A5C-4D91-4BE8-9401-89FF3D356740Q38156001-3BF48A03-25E7-4886-BEC6-A9E6DDB2E39FQ38200656-ABC44CB2-8E84-4E54-B8E6-96669F717E6AQ38242001-0EE4DE59-36BE-4157-BA58-5183EA50A408Q38244159-08DD6ED9-D704-46FA-8EC0-9EFD01F5FB5CQ38270790-92E2E464-3100-43C1-B7B7-F765310D7E36Q38291371-1400F819-02AF-4F0F-8C3A-6BB95438220DQ39326667-3358FCEF-7D54-467B-98A0-B1C53DD9390FQ40366493-1D97DFA1-2C93-4A4B-865C-2C5EFC5BF609Q41495600-82AD819E-09A4-420A-8208-DD7D7FD6BFA9Q41902527-7315416F-E883-49EC-BFDF-FA3D688214E6Q47573914-000A59FF-9F39-4F3D-A548-894B444F89C1Q48285675-7B54D9FE-5354-4E11-8B45-A96496570EBDQ48371140-8B2F5970-3450-481D-AD8D-12AF22FED036Q48386112-055E6D95-CC0B-4443-9EA7-05FE2D55DC2AQ48390325-6EDAF4CC-37D3-4815-819D-44567CC25630Q50224610-9022BAE4-7C6E-47A7-9C92-412E660A4029Q53682426-04E9B76B-D292-44B9-8F53-0E04CB274162
P2860
Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@ast
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@en
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@nl
type
label
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@ast
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@en
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@nl
prefLabel
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@ast
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@en
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@nl
P2093
P1476
Vortioxetine (Lu AA21004) in g ...... ebo-controlled clinical trial.
@en
P2093
Atul R Mahableshwarkar
David V Sheehan
Leszek Bidzan
Mingjin Yan
Paula Jacobsen
P304
P356
10.1016/J.EURONEURO.2012.07.012
P407
P577
2012-08-14T00:00:00Z